The primary objective of serialization is to protect patients. This is ensured by processes and control mechanisms that ensure that only original and manufacturer-approved drugs reach pharmacies and hospitals.

Sustainable changes in almost all areas

Manufacturers, contract manufacturers, wholesalers, repackagers, parallel importers – or in other words: the entire pharmaceutical industry need to invest in infrastructure, personnel and process adjustment. Process workshops take place against the background of serialization, tasks and responsibilities between departments are redefined. Serialization forces companies to digitize and create a new way of collaboration.

Secondary and perspective added values

Serialization can be seen as a burden or an opportunity. Some companies use the favor of the hour to optimize old processes and established procedures to make them more efficient. The modernization of the infrastructure as well as the increased transparency in production, can open possibilities for medium-term advantages.

Serialization creates the basis for added value and direct communication between manufacturer and patient. Consulting and service offerings come to the fore. “Value-added services” can further expand the relationship between manufacturers and patients. To do this, the value-added services

• offer comprehensible benefit for the patient
• promote patient dialogue
• provide additional transparency
• understand customers and develop tailored offers

Additional offers are created through the combination of different technologies. In this way, the now serialized and clearly identifiable drugs can be enriched with additional information, for example with temperature loggers in logistics. The long-term benefits of serialization will be strongly defined by those who know how to use it.